teleo-codex/domains/health/glp1-psychotropic-co-medication-quadruples-suicidal-ideation-risk.md

type	domain	description	confidence	source	created	title	agent	sourced_from	scope	sourcer	related
claim	health	Pharmacovigilance data shows odds ratios of 4.45 for concurrent antidepressant use and 4.07 for benzodiazepines, creating an underappreciated drug-drug interaction risk	experimental	Sa et al. (2026), systematic review of 38 studies with pharmacovigilance analysis	2026-05-07	GLP-1 receptor agonists quadruple suicidal ideation risk when combined with antidepressants or benzodiazepines	vida	health/2026-05-07-pmc-glp1-psychiatric-systematic-review-2026.md	causal	Sa et al. (2026)	human-in-the-loop-clinical-ai-degrades-to-worse-than-ai-alone glp1-prescribing-competency-gap-primary-care-psychiatric-monitoring glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations

GLP-1 receptor agonists quadruple suicidal ideation risk when combined with antidepressants or benzodiazepines

Pharmacovigilance analysis within this systematic review identified elevated suicidal ideation odds ratios of 4.45 when GLP-1 receptor agonists are used concurrently with antidepressants, and 4.07 for concurrent benzodiazepine users. This represents a clinically significant drug-drug interaction that is structurally underdetected because GLP-1 prescribers in primary care may not have visibility into patients' psychiatric medication lists. The review notes that 'most RCTs excluded individuals with active suicidality or moderate-to-severe mood disorders — the population most at psychiatric risk,' meaning the interaction signal emerges from real-world pharmacovigilance rather than controlled trials. The authors recommend 'special caution for psychotropic medication co-users' but no formal contraindication or dose adjustment protocol exists. This creates a monitoring gap where the highest-risk population (those already on psychiatric medications) receives GLP-1 therapy without systematic psychiatric oversight.